Important Notice: Our web hosting provider recently started charging us for additional visits, which was unexpected. In response, we're seeking donations. Depending on the situation, we may explore different monetization options for our Community and Expert Contributors. It's crucial to provide more returns for their expertise and offer more Expert Validated Answers or AI Validated Answers. Learn more about our hosting issue here.

How is tissue plasminogen activator (t-PA) used to treat brain attack?

0
Posted

How is tissue plasminogen activator (t-PA) used to treat brain attack?

0

For a number of years, t-PA (Activase® Alteplase) has been used in the treatment of acute myocardial infarction. The U.S. Food and Drug Administration (FDA) has approved the use of t-PA to reestablish blood supply to tissue damaged in an acute ischemic stroke. In the United States, a two-part double-blind placebo controlled trial conducted by the NINDS has provided a framework for patient selection and treatment protocols for brain attack. Part I of the NINDS trial compared neurological outcomes at 24 hours among patients given t-PA with the outcomes of a placebo group. Patients in the study group were given t-PA within three hours after the onset of symptoms. Part II assessed patient outcomes three months after treatment with t-PA. The study found no significant neurological improvement in 24 hours among patients who received t-PA as compared with the placebo group. However, at three months, patients in the t-PA group were at least 30 percent more likely than those in the placebo grou

0

For a number of years, t-PA (Activase® Alteplase) has been used in the treatment of acute myocardial infarction. The U.S. Food and Drug Administration (FDA) has approved the use of t-PA to reestablish blood supply to tissue damaged in an acute ischemic stroke. In the United States, a two-part double-blind placebo controlled trial conducted by the NINDS has provided a framework for patient selection and treatment protocols for brain attack. Part I of the NINDS trial compared neurological outcomes at 24 hours among patients given t-PA with the outcomes of a placebo group. Patients in the study group were given t-PA within three hours after the onset of symptoms. Part II assessed patient outcomes three months after treatment with t-PA. The study found no significant neurological improvement in 24 hours among patients who received t-PA as compared with the placebo group. However, at three months, patients in the t-PA group were at least 30 percent more likely than those in the placebo grou

Related Questions

What is your question?

*Sadly, we had to bring back ads too. Hopefully more targeted.